 Biocept Inc NASDAQ:BIOC said it presented a study demonstrating the ability of its CNSide assay to identify HER2 and other actionable tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease LMD. The poster was chosen for a Spotlight Presentation at the San Antonio Breast Cancer Symposium on December 8, 2021, the company added in a statement. 